| Literature DB >> 30210344 |
Xin Feng1, Ming-Hui Li2, Jing Xia3, Da J Deng Ba1, Ling-Yu Ruan2, Yue-Xiao Xing2, Cheng Chen2, Jun-Song Wang2, Ge-Jia Zhong1.
Abstract
Liver fibrosis is a severe health problem, threatening the life quality and causing death, raising great concerns worldwide. Shi-Wei-Gan-Ning-Pill (SWGNP) is a traditional Tibetan recipe used to treat hepatic injuries; however, its hepatoprotective mechanism has not yet fully clarified. In this study, histological staining, biochemical assays, and elements determination were applied to evaluate the anti-fibrotic efficacy of SWGNP on a carbon tetrachloride (CCl4) induced hepato-fibrosis rat model. NMR-based metabolomics combined with orthogonal partial least squares-discriminant analysis (OPLS-DA), canonical regression analysis, and correlation networks analysis was used to characterize the potential biomarkers as well as metabolic pathways associated with the hepatoprotective activity of SWGNP. The results showed that SWGNP could significantly attenuate the pathological changes and decrease the levels of fibrosis markers (ColIV, HA, LN, and PCIII), and regulate the disordered elements distribution. Multivariate analysis and correlation network analysis revealed that SWGNP could protect rats against CCl4-induced liver fibrosis through anti-oxidation, repairing the impaired energy metabolisms and reversing the disturbed amino acids and nucleic acids metabolisms. In conclusion, this integrated metabolomics approach provided new insights into the mechanism of the hepatoprotective effect of SWGNP in liver fibrosis disease.Entities:
Keywords: NMR; Shi-Wei-Gan-Ning-Pill; Tibetan medical formula; carbon tetrachloride; liver fibrosis; metabolic profiling
Year: 2018 PMID: 30210344 PMCID: PMC6123542 DOI: 10.3389/fphar.2018.00965
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Potential marker metabolites in rat liver extracts identified by 1H-NMR and their 530 variations among groups and the associated p-values.
| Compounds | Model/control | Low/model | Medium/model | High/model | ||||
|---|---|---|---|---|---|---|---|---|
| log2(FC) | log2(FC) | log2(FC) | log2(FC) | |||||
| Hypoxanthine | –1.11 | ∗∗∗ | 0.06 | –0.32 | –0.43 | ∗∗ | ||
| Inosine | –1.06 | ∗∗∗ | 0.7 | ∗∗ | –0.12 | 1.25 | ∗∗∗ | |
| Xanthine | –1.04 | ∗∗∗ | 0.06 | –0.32 | –0.43 | ∗∗ | ||
| Fumarate | –0.96 | ∗∗∗ | 0.11 | 0.38 | 0.44 | ∗∗ | ||
| Glucose | –0.77 | ∗∗∗ | 0.07 | 0.01 | –0.17 | |||
| Niacinamide | –0.68 | ∗∗ | –0.12 | –0.04 | –0.07 | |||
| NADPH | –0.57 | ∗∗ | 0.26 | ∗ | –0.01 | 0 | ||
| 3-Hydroxybutyrate | –0.57 | ∗∗ | 0.14 | –0.18 | 0.01 | |||
| Tyrosine | –0.43 | ∗∗ | –0.07 | –0.07 | –0.76 | ∗∗∗ | ||
| Histidine | –0.37 | –0.14 | 0.19 | 0.04 | ||||
| NAD+ | –0.28 | 0.39 | –0.03 | 0.28 | ||||
| Isoleucine | –0.23 | 0.06 | –0.17 | –0.47 | ∗∗∗ | |||
| Lysine | –0.21 | ∗∗ | –0.22 | –0.15 | –0.45 | ∗∗∗ | ||
| Leucine | –0.19 | –0.06 | –0.18 | –0.67 | ∗∗∗ | |||
| Creatine | –0.17 | –0.12 | –0.09 | –0.04 | ||||
| Choline | –0.14 | 0.2 | –0.12 | –0.22 | ||||
| Acetate | –0.1 | 0.12 | –0.07 | 0.18 | ∗ | |||
| Valine | –0.09 | –0.03 | –0.18 | –0.69 | ∗∗∗ | |||
| Phenylalanine | 0.05 | 0.04 | –0.03 | –0.81 | ∗∗∗ | |||
| Betaine | 0.11 | –0.07 | 0.3 | 0.08 | ||||
| 5,6-Dihydrouracil | 0.15 | 0.18 | 0 | 0.06 | ||||
| Glycine | 0.27 | –0.18 | –0.3 | –0.4 | ∗∗ | |||
| Glutamate | 0.29 | –0.15 | –0.09 | –0.17 | ||||
| Uridine | 0.29 | ∗ | 0.26 | 0.04 | 0.42 | ∗ | ||
| Uracil | 0.33 | ∗ | –0.14 | 0.29 | –0.25 | ∗ | ||
| Aspartate | 0.33 | –0.29 | –0.17 | –0.27 | ∗ | |||
| Ethanol | 0.39 | –0.94 | ∗∗∗ | –0.56 | ∗ | –1.22 | ∗∗∗ | |
| Glutamine | 0.43 | ∗∗ | 0.15 | 0.06 | 0.37 | ∗∗∗ | ||
| Alanine | 0.49 | ∗∗∗ | –0.09 | –0.12 | –0.3 | ∗ | ||
| Dimethylamine | 0.52 | ∗∗ | –0.22 | –0.17 | –0.15 | |||
| UDP-galactose | 0.53 | ∗∗ | 0.41 | 0.15 | 0.67 | ∗∗∗ | ||
| Glutathione | 0.54 | ∗ | 0.03 | –0.06 | 0.32 | ∗∗ | ||
| Succinate | 0.57 | ∗∗ | –0.14 | –0.3 | –0.2 | |||
| 0.59 | ∗∗∗ | 0.1 | 0.16 | 0.2 | ∗∗ | |||
| Sarcosine | 0.63 | ∗ | 0.18 | –0.04 | 0.06 | |||
| Phosphocholine | 0.63 | ∗∗ | –0.07 | 0.06 | 0.19 | ∗ | ||
| Phosphoethanolamine | 1.13 | ∗∗∗ | 0.04 | 0.87 | 0.74 | |||
| UDP-glucose | 1.21 | ∗∗ | 0.43 | 0.08 | 0.97 | ∗∗∗ | ||
| Lactate | 1.23 | ∗∗∗ | –0.2 | 0 | –0.12 | |||
Potential marker metabolites in rat serum identified by 1H-NMR and their variations among groups and the associated p values.
| Compounds | Model/control | Low/model | Medium/model | High/model | ||||
|---|---|---|---|---|---|---|---|---|
| log2(FC) | log2(FC) | log2(FC) | log2(FC) | |||||
| Succinate | –0.74 | –0.23 | –0.16 | –0.04 | ||||
| GABA | –0.57 | –0.08 | –0.05 | 0.08 | ||||
| 3-Hydroxybutyrate | –0.46 | –0.04 | 0.02 | 0.2 | ||||
| Glucose | –0.45 | ∗∗ | 0.05 | 0.12 | 0 | |||
| Acetoacetate | –0.32 | –0.4 | –0.28 | –0.77 | ||||
| Tyrosine | –0.27 | 0.12 | 0.03 | 0.26 | ∗∗ | |||
| Tryptophan | –0.19 | 0.1 | –0.1 | 0.27 | ||||
| 3-Hydroxyisobutyrate | –0.17 | –0.14 | 0.21 | 0.1 | ||||
| Uridine | –0.03 | –0.14 | –0.01 | 0.05 | ||||
| Formate | –0.02 | –0.25 | –0.27 | 0.04 | ||||
| Inosine | –0.01 | 0.03 | –0.06 | 0.1 | ||||
| Creatine | 0.00 | –0.22 | –0.23 | –0.04 | ∗∗ | |||
| Methanol | 0.02 | 0.12 | 0.04 | –1.12 | ||||
| Phenylalanine | 0.04 | 0.06 | –0.09 | 0.18 | ||||
| Lysine | 0.06 | –0.02 | –0.19 | 0.13 | ||||
| Pyruvate | 0.08 | 0.49 | –0.25 | 0.33 | ||||
| Glutamine | 0.18 | ∗ | –0.08 | –0.19 | –0.03 | |||
| Acetate | 0.27 | –0.15 | –0.28 | 0.13 | ||||
| Citrate | 0.31 | 0.02 | –0.13 | 0.15 | ||||
| Isoleucine | 0.32 | ∗ | –0.08 | –0.24 | 0.11 | |||
| Valine | 0.41 | ∗∗ | –0.14 | –0.27 | 0.1 | |||
| Ethanol | 0.47 | 0.02 | –0.13 | 0.15 | ||||
| Lactate | 0.53 | ∗ | –0.08 | –0.01 | 0.32 | |||
| Alanine | 0.65 | ∗ | 0.04 | –0.09 | 0.22 | |||
| Leucine | 0.74 | ∗∗ | –0.13 | –0.23 | 0.08 | |||
| Glycine | 0.82 | ∗∗ | –0.06 | –0.07 | 0.07 | |||
| Histamine | 0.95 | 0.06 | –0.07 | 0.13 | ||||
| Acetone | 1.01 | ∗∗ | –0.42 | –0.51 | –0.32 | |||